Home / NEWS / Here's Why bluebird bio Dropped 13.3% in September

Here's Why bluebird bio Dropped 13.3% in September


Here's Why bluebird bio Dropped 13.3% in September


The biopharma's multimonth stock slide continued, courtesy of promising preclinical results released by Amgen.


The biopharma's multimonth stock slide continued, courtesy of promising preclinical results released by Amgen.


Here's Why bluebird bio Dropped 13.3% in September
Here's Why bluebird bio Dropped 13.3% in September Here's Why bluebird bio Dropped 13.3% in September Reviewed by Unknown on 11:33 AM Rating: 5

No comments:

Subscribe to: Post Comments ( Atom )
Powered by Blogger.